Should enzyme-inducing antiepileptic drugs be considered first-line agents?
Scott Mintzer
Department of Neurology, Thomas Jefferson University
Search for more papers by this authorRichard T. Mattson
Department of Neurology, Yale University School of Medicine, New Haven, Connecticut, U.S.A.
Search for more papers by this authorScott Mintzer
Department of Neurology, Thomas Jefferson University
Search for more papers by this authorRichard T. Mattson
Department of Neurology, Yale University School of Medicine, New Haven, Connecticut, U.S.A.
Search for more papers by this authorSummary
Despite the introduction of a host of new antiepileptic drugs (AEDs) over the last 20 years, the older agents, which are potent inducers of the cytochrome P450 (CYP450) system, remain the AEDs most commonly prescribed throughout the world. At the same time, data have gradually and continuously emerged regarding the possible adverse consequences of CYP450 induction, such that it is now appropriate to pose the question of whether the inducing drugs should still be considered first-line agents for the treatment of focal epilepsy. In this article we review the evidence suggesting that these drugs may have many detrimental metabolic effects, along with the data concerning their relative efficacy compared to the newer, noninducing AEDs. We conclude that longer and better-powered studies are needed to truly establish whether the newer AEDs are equivalent in efficacy to the older, inducing agents. Pending this, however, the extant data are sufficiently concerning to suggest that it may be prudent to start with noninducing AEDs unless there is a clear indication for one of the inducing drugs.
References
- Aggarwal A, Singh V, Batra S, Faridi MMA, Sharma S. (2009) Effect of carbamazepine therapy on serum lipids in children with partial epilepsy. Pediatr Neurol 40: 94–97.
- Annegers JF, Hauser WA, Shirts SB. (1984) Heart disease mortality and morbidity in patients with epilepsy. Epilepsia 25: 699–704.
- Apeland T, Mansoor MA, Strandjord RE, Vefring H, Kristensen O. (2001) Folate, homocysteine and methionine loading in patients on carbamazepine. Acta Neurol Scand 103: 294–299.
- Ascherio A, Munger KL. (2007) Environmental risk factors for multiple sclerosis. Part II: noninfectious factors. Ann Neurol 61: 504–513.
- Baciewicz AM, Baciewicz FAJ. (1989) Cyclosporine pharmacokinetic drug interactions. Am J Surg 157: 264–271.
- Bill PA, Vigonius U, Pohlmann H, Guerreiro CAM, Kochen S, Saffer D, Moore A. (1997) A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in adults with previously untreated epilepsy. Epilepsy Res 27: 195–204.
- Bramswig S, Sudhop T, Luers C, Von Bergmann K, Berthold HK. (2003) Lipoprotein(a) concentration increases during treatment with carbamazepine. Epilepsia 44: 457–460.
- Brodie MJ, Richens A, Yuen AW. (1995) Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. UK lamotrigine/carbamazepine monotherapy trial group. Lancet 345: 476–479.
- Brodie MJ, Overstall PW, Giorgi L. (1999) Multicentre, double-blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK lamotrigine elderly study group. Epilepsy Res 37: 81–87.
- Brodie MJ, Wroe SJ, Dean AD, Holdich TA, Whitehead J, Stevens JW. (2002) Efficacy and safety of remacemide versus carbamazepine in newly diagnosed epilepsy: comparison by sequential analysis. Epilepsy Behav 3: 140–146.
- Brodie MJ, Perucca E, Ryvlin P, Ben-Menachem E, Meencke HJ. (2007) Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology 68: 402–408.
- Calandre EP, Rodriquez-Lopez C, Blazquez A, Cano D. (1991) Serum lipids, lipoproteins and a polipoproteins A and B in epileptic patients treated with valproic acid, carbamazepine or phenobarbital. Acta Neurol Scand 83: 250–253.
- Callaghan N, Kenny RA, O’Neill B, Crowley M, Goggin T. (1985) A prospective study between carbamazepine, phenytoin and sodium valproate as monotherapy in previously untreated and recently diagnosed patients with epilepsy. J Neurol Neurosurg Psychiatry 48: 639–644.
- Chadwick D. (1999) Safety and efficacy of vigabatrin and carbamazepine in newly diagnosed epilepsy: a multicentre randomised double-blind study. Vigabatrin European monotherapy study group. Lancet 354: 13–19.
- Cockerell OC, Johnson AL, Sander JW, Hart YM, Goodridge DM, Shorvon SD. (1994) Mortality from epilepsy: results from a prospective population-based study. Lancet 344: 918–921.
- Dam M, Ekberg R, Loyning Y, Waltimo O, Jakobsen K. (1989) A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Res 3: 70–76.
- Danesh J, Collins R, Peto R. (2000) Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation 102: 1082–1085.
- Dent CE, Richens A, Rowe DJ, Stamp TC. (1970) Osteomalacia with long-term anticonvulsant therapy in epilepsy. Br Med J 4: 69–72.
- Ding D, Wang W, Wu J, Ma G, Dai X, Yang B, Wang T, Yuan C, Hong Z, De Boer HM, Prilipko L, Sander JW. (2006) Premature mortality in people with epilepsy in rural China: a prospective study. Lancet Neurol 5: 823–827.
- Ecevit C, Aydogan A, Kavakli T, Altinoz S. (2004) Effect of carbamazepine and valproate on bone mineral density. Pediatr Neurol 31: 279–282.
- Eiris J, Novo-Rodriguez MI, Del Rio M, Meseguer P, Del Rio MC, Castro-Gago M. (2000) The effects on lipid and apolipoprotein serum levels of long-term carbamazepine, valproic acid and phenobarbital therapy in children with epilepsy. Epilepsy Res 41: 1–7.
- Ensrud KE, Walczak TS, Blackwell T, Ensrud ER, Bowman PJ, Stone KL. (2004) Antiepileptic drug use increases rates of bone loss in older women: a prospective study. Neurology 62: 2051–2057.
- Ensrud KE, Walczak TS, Blackwell TL, Ensrud ER, Barrett-Connor E, Orwoll ES. (2008) Antiepileptic drug use and rates of hip bone loss in older men: a prospective study. Neurology 71: 723–730.
- Evatt ML, DeLong MR, Khazai N, Rosen A, Triche S. (2008) Prevalence of vitamin D insufficiency in patients with Parkinson disease and Alzheimer disease. Arch Neurol 65: 1348–1352.
- Ficker DM, Privitera M, Krauss G, Kanner A, Moore JL, Glauser T. (2005) Improved tolerability and efficacy in epilepsy patients with extended-release carbamazepine. Neurology 65: 593–595.
- Formea CM, Evans CG, Karlix JL. (2005) Altered cytochrome p450 metabolism of calcineurin inhibitors: case report and review of the literature. Pharmacotherapy 25: 1021–1029.
- French JA, Kanner AM, Bautista J, Abou-Khalil B, Browne T, Harden CL, Theodore WH, Bazil C, Stern J, Schachter SC, Bergen D, Hirtz D, Montouris GD, Nespeca M, Gidal B, Marks WJ Jr, Turk WR, Fischer JH, Bourgeois B, Wilner A, Faught RE Jr, Sachdeo RC, Beydoun A, Glauser TA. (2004) Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy: report of the therapeutics and technology assessment subcommittee and quality standards subcommittee of the American academy of neurology and the American epilepsy society. Neurology 62: 1252–1260.
- Gaitatzis A, Carroll K, Majeed A, W Sander J. (2004) The epidemiology of the comorbidity of epilepsy in the general population. Epilepsia 45: 1613–1622.
- Gamble CL, Williamson PR, Marson AG. (2006) Lamotrigine versus carbamazepine monotherapy for epilepsy. Cochrane Database Syst Rev CD001031.
- Gibbons GF. (2002) The role of cytochrome P450 in the regulation of cholesterol biosynthesis. Lipids 37: 1163–1170.
- Gidal BE, French JA, Grossman P, Le Teuff G. (2009) Assessment of potential drug interactions in patients with epilepsy: impact of age and sex. Neurology 72: 419–425.
- Glauser T, Ben-Menachem E, Bourgeois B, Cnaan A, Chadwick D, Guerreiro C, Kalviainen R, Mattson R, Perucca E, Tomson T. (2006) ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 47: 1094–1120.
- Gough H, Goggin T, Bissessar A, Baker M, Crowley M, Callaghan N. (1986) A comparative study of the relative influence of different anticonvulsant drugs, UV exposure and diet on vitamin D and calcium metabolism in out-patients with epilepsy. Q J Med 59: 569–577.
- Guerreiro MM, Vigonius U, Pohlmann H, De Manreza MLG, Fejerman N, Antoniuk SA, Moore A. (1997) A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in children and adolescents with epilepsy. Epilepsy Res 27: 205–213.
- Hamed SA, Hamed EA, Hamdy R, Nabeshima T. (2007) Vascular risk factors and oxidative stress as independent predictors of asymptomatic atherosclerosis in adult patients with epilepsy. Epilepsy Res 74: 183–192.
- Herzog AG, Drislane FW, Schomer DL, Pennell PB, Bromfield EB, Dworetzky BA, Farina EL, Frye CA. (2005) Differential effects of antiepileptic drugs on sexual function and hormones in men with epilepsy. Neurology 65: 1016–1020.
- Hoikka V, Alhava EM, Karjalainen P, Keranen T, Savolainen KE, Riekkinen P, Korhonen R. (1984) Carbamazepine and bone mineral metabolism. Acta Neurol Scand 70: 77–80.
- Isojarvi JI, Pakarinen AJ, Myllyla VV. (1993) Serum lipid levels during carbamazepine medication. A prospective study [see comment]. Arch Neurol 50: 590–593.
- Isojarvi JI, Pakarinen AJ, Rautio A, Pelkonen O, Myllyla VV. (1994) Liver enzyme induction and serum lipid levels after replacement of carbamazepine with oxcarbazepine. Epilepsia 35: 1217–1220.
- Kandutsch AA, Chen HW, Heiniger HJ. (1978) Biological activity of some oxygenated sterols. Science 201: 498–501.
- Karceski S, Morrell MJ, Carpenter D. (2005) Treatment of epilepsy in adults: expert opinion, 2005. Epilepsy Behav. 7 Suppl 1: S1–64; quiz S65–7.
- Kim SH, Lee JW, Choi KG, Chung HW, Lee HW. (2007) A 6-month longitudinal study of bone mineral density with antiepileptic drug monotherapy. Epilepsy Behav 10: 291–295.
- Kwan P, Brodie MJ. (2000) Early identification of refractory epilepsy. N Engl J Med 342: 314–319.
- Lamberg-Allardt C, Wilska M, Saraste KL, Gronlund T. (1990) Vitamin D status of ambulatory and nonambulatory mentally retarded children with and without carbamazepine treatment. Ann Nutr Metab 34: 216–220.
- Lofgren E, Tapanainen JS, Koivunen R, Pakarinen A, Isojarvi JI. (2006) Effects of carbamazepine and oxcarbazepine on the reproductive endocrine function in women with epilepsy. Epilepsia 47: 1441–1446.
- Luoma PV, Sotaniemi EA, Arranto AJ. (1983) Serum LDL cholesterol, the LDL/HDL cholesterol ratio and liver microsomal enzyme induction evaluated by antipyrine kinetics. Scand J Clin Lab Invest 43: 671–675.
- Luoma PV, Sotaniemi EA, Pelkonen RO, Pirttiaho HI. (1985) Serum low-density lipoprotein and high-density lipoprotein cholesterol, and liver size in subjects on drugs inducing hepatic microsomal enzymes. Eur J Clin Pharmacol 28: 615–618.
- Lyngstad Brechan MA, Taubøll E, Jemtland R, Godang K, Bollerslev J, Gjerstad L. (2005) Carbamazepine may induce osteoporosis by increasing bone turnover in postmenopausal women. Epilepsia 46: 178.
- Marson AG, Al-Kharusi AM, Alwaidh M, Appleton R, Baker GA, Chadwick DW, Cramp C, Cockerell OC, Cooper PN, Doughty J, Eaton B, Gamble C, Goulding PJ, Howell SJ, Hughes A, Jackson M, Jacoby A, Kellett M, Lawson GR, Leach JP, Nicolaides P, Roberts R, Shackley P, Shen J, Smith DF, Smith PE, Smith CT, Vanoli A, Williamson PR. (2007) The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet 369: 1000–1015.
- Mattson RH, Cramer JA, Collins JF et al. (1985) Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. N Engl J Med 313: 145–151.
- Mattson RH, Cramer JA, Collins JF. (1992) A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. The Department of Veterans Affairs epilepsy cooperative study No. 264 group. N Engl J Med 327: 765–771.
- Melamed ML, Michos ED, Post W, Astor B. (2008) 25-hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med 168: 1629–1637.
- Mintzer S, Boppana P, Toguri J, DeSantis A. (2006) Vitamin D levels and bone turnover in epilepsy patients taking carbamazepine or oxcarbazepine. Epilepsia 47: 510–515.
- Mintzer S, Skidmore CT, Abidin CJ, Morales MC, Chervoneva I, Capuzzi DM, Sperling MR. (2009) Effects of antiepileptic drugs on lipids, homocysteine, and C-reactive protein. Ann Neurol 65: 448–456.
- Muck W, Ahr G, Kuhlmann J. (1995) Nimodipine. Potential for drug-drug interactions in the elderly. Drugs Aging 6: 229–242.
- Muuronen A, Kaste M, Nikkila EA, Tolppanen EM. (1985) Mortality from ischaemic heart disease among patients using anticonvulsive drugs: a case-control study. Br Med J (Clin Res Ed) 291: 1481–1483.
- Nation RL, Evans AM, Milne RW. (1990) Pharmacokinetic drug interactions with phenytoin (Part I). Clin Pharmacokinet 18: 37–60.
- Nebert DW, Russell DW. (2002) Clinical importance of the cytochromes P450. Lancet 360: 1155–1162.
- Nikolaos T, Stylianos G, Chryssoula N, Irini P, Christos M, Dimitrios T, Konstantinos P, Antonis T. (2004) The effect of long-term antiepileptic treatment on serum cholesterol (TC, HDL, LDL) and triglyceride levels in adult epileptic patients on monotherapy. Med Sci Monit 10: MT50–2.
- Nilsson L, Tomson T, Farahmand BY, Diwan V, Persson PG. (1997) Cause-specific mortality in epilepsy: a cohort study of more than 9,000 patients once hospitalized for epilepsy. Epilepsia 38: 1062–1068.
- O’Brien MD, Guillebaud J. (2006) Contraception for women with epilepsy. Epilepsia 47: 1419–1422.
- O’Neill B, Callaghan N, Stapleton M, Molloy W. (1982) Serum elevation of high density lipoprotein (HDL) cholesterol in epileptic patients taking carbamazepine or phenytoin. Acta Neurol Scand 65: 104–109.
- Oberndorfer S, Piribauer M, Marosi C, Lahrmann H, Hitzenberger P, Grisold W. (2005) P450 enzyme inducing and non-enzyme inducing antiepileptics in glioblastoma patients treated with standard chemotherapy. J Neurooncol 72: 255–260.
- Pack AM, Morrell MJ, Marcus R, Holloway L, Flaster E, Done S, Randall A, Seale C, Shane E. (2005) Bone mass and turnover in women with epilepsy on antiepileptic drug monotherapy. Ann Neurol 57: 252–257.
- Pack AM, Morrell MJ, Randall A, McMahon DJ, Shane E. (2008) Bone health in young women with epilepsy after one year of antiepileptic drug monotherapy. Neurology 70: 1586–1593.
- Prasad K. (2006) C-reactive protein (CRP)-lowering agents. Cardiovasc Drug Rev 24: 33–50.
- Privitera MD, Brodie MJ, Mattson RH, Chadwick DW, Neto W, Wang S. (2003) Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy. Acta Neurol Scand 107: 165–175.
- Ramael S, Daoust A, Otoul C, Toublanc N, Troenaru M, Lu ZS, Stockis A. (2006) Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study. Epilepsia 47: 1128–1135.
- Ravaglia G, Forti P, Maioli F, Martelli M, Servadei L, Brunetti N, Porcellini E, Licastro F. (2005) Homocysteine and folate as risk factors for dementia and Alzheimer disease. Am J Clin Nutr 82: 636–643.
- Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. (1997) Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 336: 973–979.
- Rowan AJ, Ramsay RE, Collins JF, Pryor F, Boardman KD, Uthman BM, Spitz M, Frederick T, Towne A, Carter GS, Marks W, Felicetta J, Tomyanovich ML. (2005) New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine, and carbamazepine. Neurology 64: 1868–1873.
- Schwaninger M, Ringleb P, Winter R, Kohl B, Fiehn W, Rieser PA, Walter-Sack I. (1999) Elevated plasma concentrations of homocysteine in antiepileptic drug treatment. Epilepsia 40: 345–350.
- Schwaninger M, Ringleb P, Annecke A, Winter R, Kohl B, Werle E, Fiehn W, Rieser PA, Walter-Sack I. (2000) Elevated plasma concentrations of lipoprotein(a) in medicated epileptic patients. J Neurol 247: 687–690.
- Sheth RD, Wesolowski CA, Jacob JC, Penney S, Hobbs GR, Riggs JE, Bodensteiner JB. (1995) Effect of carbamazepine and valproate on bone mineral density. J Pediatr 127: 256–262.
- Souverein PC, Webb DJ, Weil JG, Van Staa TP, Egberts AC. (2006) Use of antiepileptic drugs and risk of fractures: case-control study among patients with epilepsy. Neurology 66: 1318–1324.
- Spence JD. (2007) Homocysteine-lowering therapy: a role in stroke prevention? Lancet Neurol 6: 830–838.
- Spina E, Pisani F, Perucca E. (1996) Clinically significant pharmacokinetic drug interactions with carbamazepine An update. Clin Pharmacokinet 31: 198–214.
- Strolin Benedetti M, Ruty B, Baltes E. (2005) Induction of endogenous pathways by antiepileptics and clinical implications. Fundam Clin Pharmacol 19: 511–529.
- Talbot JA, Sheldrick R, Caswell H, Duncan S. (2008) Sexual function in men with epilepsy: how important is testosterone? Neurology 70: 1346–1352.
- Tjellesen L, Christiansen C. (1982) Serum vitamin D metabolites in epileptic patients treated with 2 different anti-convulsants. Acta Neurol Scand 66: 335–341.
- Tsiropoulos I, Andersen M, Nymark T, Lauritsen J, Gaist D, Hallas J. (2008) Exposure to antiepileptic drugs and the risk of hip fracture: a case-control study. Epilepsia 49: 2092–2099.
- Verrotti A, Domizio S, Angelozzi B, Sabatino G, Morgese G, Chiarelli F. (1997) Changes in serum lipids and lipoproteins in epileptic children treated with anticonvulsants. J Paediatr Child Health 33: 242–245.
- Verrotti A, Basciani F, Domizio S, Sabatino G, Morgese G, Chiarelli F. (1998) Serum lipids and lipoproteins in patients treated with antiepileptic drugs. Pediatr Neurol 19: 364–367.
- Verrotti A, Greco R, Morgese G, Chiarelli F. (2000a) Increased bone turnover in epileptic patients treated with carbamazepine. Ann Neurol 47: 385–388.
- Verrotti A, Pascarella R, Trotta D, Giuva T, Morgese G, Chiarelli F. (2000b) Hyperhomocysteinemia in children treated with sodium valproate and carbamazepine. Epilepsy Res 41: 253–257.
- Verrotti A, Greco R, Latini G, Morgese G, Chiarelli F. (2002) Increased bone turnover in prepubertal, pubertal, and postpubertal patients receiving carbamazepine. Epilepsia 43: 1488–1492.
- Vestergaard P, Rejnmark L, Mosekilde L. (2004) Fracture risk associated with use of antiepileptic drugs. Epilepsia 45: 1330–1337.
- Wada K, Takada M, Ueda T, Ochi H, Kotake T, Morishita H, Hanatani A, Nakatani T. (2007) Drug interactions between tacrolimus and phenytoin in Japanese heart transplant recipients: 2 case reports. Int J Clin Pharmacol Ther 45: 524–528.
- Wheless JW, Clarke DF, Carpenter D (2005) Treatment of pediatric epilepsy: expert opinion, 2005. J Child Neurol. 20 suppl 1: S1–56; quiz S59–60.